A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns. This divergence was stark: the tech-heavy Nasdaq struggled, losing 0.2%, while the Dow rallied.
This shift away from tech was triggered by a series of negative catalysts in the AI sector. AI cloud provider CoreWeave slid on disappointing guidance, while chip darling Nvidia pulled back after SoftBank sold its stake. This "hurt the AI trade," dragging down related names like Micron and Oracle.
As capital left tech, it sought safety in "higher quality" defensive names. Health care giants like Merck, Amgen, and Johnson & Johnson saw significant buying, boosting the Dow.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Let’s dig into the relative performance of Neogen (NASDAQ:NEOG) and its peers as we unravel the now-completed Q3 medical devices & supplies - diversified earnings season.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential.
However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.
Neogen’s third quarter results were met with a strong positive market reaction, despite reporting a year-over-year sales decline. Management attributed the quarter’s performance to ongoing operational challenges, including inefficiencies in sample collection and excess inventory, which impacted margins. CEO Mikhael Nassif pointed to improvements in core food safety products and stabilization efforts in the Animal Safety segment, while also acknowledging temporary distributor-related disruptions in Petrifilm. The company’s actions to streamline costs, such as a global workforce reduction and portfolio optimization, were central to mitigating near-term pressures.
Unprofitable companies face headwinds as they struggle to keep operating expenses under control.
Some may be investing heavily, but the majority fail to convert spending into sustainable growth.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Life sciences company Neogen (NASDAQ:NEOG) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 3.6% year on year to $209.2 million. The company’s full-year revenue guidance of $830 million at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.
Shares of life sciences company Neogen (NASDAQ:NEOG)
jumped 21.4% in the morning session after the company reported third-quarter 2025 financial results that surpassed revenue expectations while its earnings were in line with estimates.
Life sciences company Neogen (NASDAQ:NEOG) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales fell by 3.6% year on year to $209.2 million. The company’s full-year revenue guidance of $830 million at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $0.04 per share was in line with analysts’ consensus estimates.
Neogen's Q1 FY2026 results show a mixed performance, with revenue beating estimates but adjusted EPS slightly missing. The stock rose as investors focused on the revenue beat and cost-saving initiatives.
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Neogen has gotten torched over the last six months - since April 2025, its stock price has dropped 30.9% to $5.80 per share. This may have investors wondering how to approach the situation.
Shares of life sciences company Neogen (NASDAQ:NEOG)
jumped 2.6% in the afternoon session after the company's shares rebounded following a series of recent developments, including an upcoming earnings announcement and a renewed sponsorship agreement.
Gainers SciSparc (NASDAQ: SPRC) shares increased by 28.2% to $5.68 during Monday's after-market session. The company's market cap stands at $2.2 million.
Shares of life sciences company Neogen (NASDAQ:NEOG)
fell 7.2% in the morning session after the company announced the planned departure of its Chief Financial Officer and Chief Operating Officer, David Naemura.
A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this trend is that much of the recent market gains were concentrated in the "AI trade," which includes these large technology and semiconductor companies. So this could also mean that some investors are locking in some gains ahead of more definitive feedback from the Fed.
